Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 9/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | STAT1 | P42224 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746047 | 0.90 | ABL1 (0.70) | GSK3BABL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6068319 | 0.89 | DYRK1A (0.70) | GSK3BABL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4746072 | 0.85 | NPC1 (0.77) | ABL1SMN1; SMN2NPC1RAB9ASTAT1 | |
| SCHEMBL6068272 | 0.84 | ABL1 (0.60) | GSK3BABL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6067969 | 0.84 | ABL1 (0.64) | GSK3BABL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6067997 | 0.84 | DYRK1A (0.71) | ABL1SMN1; SMN2NPC1RAB9ADYRK1A | |
| SCHEMBL14189671 | 0.84 | ABL1 (0.70) | ABL1SMN1; SMN2NPC1RAB9ADYRK1A | |
| SCHEMBL19807983 | 0.84 | DYRK1A (0.79) | SMN1; SMN2NPC1RAB9ASTAT1DYRK1A | |
| SCHEMBL30561486 | 0.84 | DYRK1A (0.79) | SMN1; SMN2NPC1RAB9ASTAT1DYRK1A | |
| SCHEMBL6068125 | 0.83 | ABL1 (0.69) | ABL1SMN1; SMN2NPC1RAB9ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091227-B2 | Benzothiazole derivatives | ABBOTT GMBH & CO. KG (DE) | 2006-08-15 | — | — | US | disclosed |
| US-20030153568-A1 | Benzothiazole derivatives | BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY | 2003-08-14 | — | — | US | disclosed |
| EP-1254123-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001057008-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153568-A1 | Benzothiazole derivatives | TK1, FLT1, CDK1 | GSK3B 89/4885ABL1 7/4885SMN1; SMN2 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.